India Pharma Outlook Team | Friday, 13 February 2026
Bharat Biotech is moving into a new chapter by exploring a biologics manufacturing facility near Chennai, a move that could reshape its role in advanced drug production.
According to the Dr. Krishna Ella, the Executive Chairman of the company, the project is designed to create new biologic therapies, particularly those in the field of diabetes and other complicated diseases. This new facility would not be a vaccine or food production center but rather a special facility to produce biologics which would need higher level of appropriate technology and skills.
Dr. Ella indicated that the company is interested in developing monoclonal antibodies and other current therapeutics capabilities and use AI-driven biologics design to remain at the head of science. He stressed the fact that though research and development will still be undertaken at the current centers of Bharat Biotech, including Hyderabad and Odisha, the most products may be produced in Chennai.
Also Read: Navigating the New Era of Nitrosamine Compliance
It is said to be a long-term plan and the company has not announced any investment values and timeframes yet. Authorities also mentioned that it is still in its infancy and that key decisions concerning finances and construction are still outstanding. The Chennai plan is indicative of an overall approach to multiply the presence of Bharat Biotech beyond its conventional vaccine foundations into more complicated biologic treatments.
Tamil Nadu government has already acted with a high speed to help the idea as a memorandum of understanding has been signed in six weeks after the first talks. Dr. Ella remarked that such a rapid move was indicative of the state commitment and helped to make the dialogue speedier. Currently, the information is preliminary, yet the relocation is an indication that Bharat Biotech is ready to grow into a larger entity in the advanced biologic production.
